RoffiMPatronoCColletJ-P, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevationTask Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J2016; 37(3): 267–315.
2.
IbanezBJamesSAgewallS, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevationThe Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J2018; 39(2): 119–177.
3.
StoneGWMcLaurinBTCoxDA, et al. Bivalirudin for Patients with Acute Coronary Syndromes. New Engl J Med2006; 355(21): 2203–2216.
4.
StoneGWWitzenbichlerBGuagliumiG, et al. Bivalirudin during Primary PCI in Acute Myocardial Infarction. New Engl J Med2008; 358(21): 2218–2230.
5.
KastratiANeumannF-JSchulzS, et al. Abciximab and Heparin versus Bivalirudin for Non–ST-Elevation Myocardial Infarction. New Engl J Med2011; 365(21): 1980–1989.
6.
ErlingeDOmerovicEFröbertO, et al. Bivalirudin versus Heparin Monotherapy in Myocardial Infarction. New Engl J Med2017; 377(12): 1132–1142.
7.
ErlingeDKoulSOmerovicE, et al. Editor’s Choice- Bivalirudin versus heparin monotherapy in non-ST-segmentelevation myocardial infarction. Eur Heart J Acute Cardiovasc Care2019; 8(6): 492–501.
8.
ValgimigliMFrigoliELeonardiS, et al. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. New Engl J Med2015; 373(11): 997–1009.
9.
VenetsanosDSederholm LawessonSFröbertO, et al. Sex-related response to bivalirudin and unfractionated heparin in patients with acute myocardial infarction undergoing percutaneous coronary intervention: A subgroup analysis of the VALIDATE-SWEDEHEART trial. Eur Heart J Acute Cardiovasc Care2019; 8(6): 502–509.
10.
VölzSAngeråsOKoulS, et al. Radial versus femoral access in patients with acute coronary syndrome undergoing invasive management: A prespecified subgroup analysis from VALIDATE-SWEDEHEART. Eur Heart J Acute Cardiovasc Care2019; 8(6): 510–519.
11.
StaudacherDLPutzVHegerL, et al. Direct factor IXa inhibition with the RNA-aptamer pegnivacogin reduces platelet reactivity in vitro and residual platelet aggregation in patients with acute coronary syndromes. Eur Heart J Acute Cardiovasc Care2019; 8(6): 520–526.
12.
MaggioniAPDondiLPedriniA, et al. The use of antiplatelet agents after an acute coronary syndrome in a large community Italian setting of more than 12 million subjects. Eur Heart J Acute Cardiovasc Care2019; 8(6): 527–535.
13.
FerreiroJLAngiolilloDJ.Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome. Circulation2011; 123(7): 798–813.
14.
WiviottSDBraunwaldEMcCabeCH, et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. New Engl J Med2007; 357(20): 2001–2015.
15.
WallentinLBeckerRCBudajA, et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. New Engl J Med2009; 361(11): 1045–1057.
16.
WiviottSDBraunwaldEAngiolilloDJ, et al. Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38. Circulation2008; 118(16): 1626–1636.
17.
FranchiFRolliniFAggarwalN, et al. Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation2016; 134(11): 780–792.
18.
StoreyRFParkerWAE. Choices for Potent Platelet Inhibition in Patients With Diabetes Mellitus. Circulation2016; 134(11): 793–796.
19.
ConrottoFBertainaMRaposeiras-RoubinS, et al. Prasugrel or ticagrelor in patients with acute coronary syndrome and diabetes: a propensity matched substudy of RENAMI. Eur Heart J Acute Cardiovasc Care2019; 8(6): 536–542.
20.
RussoJJJamesTERuelM, et al. Ischemic and bleeding outcomes after coronary artery bypass grafting among patients initially treated with a P2Y12 receptor antagonist for acute coronary syndromes: Insights on timing of discontinuation of ticagrelor and clopidogrel prior to surgery. Eur Heart J Acute Cardiovasc Care2019; 8(6): 543–553.
21.
ZelnikerTARuffCTAntmanEM, et al. The efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and coronary artery disease: A meta-analysis of randomized trials. Eur Heart J Acute Cardiovasc Care2019; 8(6): 554–561.
22.
SharkawiMAMcMahonSAl JabriD, et al. Current perspectives on location of monitoring and length of stay following PPCI for ST elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care2019; 8(6): 562–570.
23.
KaulPSavuAHamzaS, et al. Outcomes of medically managed patients with myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2019; 8(6): 571–581.
